Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.72 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | AGXT | P21549 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11991410 | 0.86 | TAAR1 (0.62) | TAAR1AOC3CHRM2CHRM1CHRM3 | |
| (S)-M-Methoxyamphetamine SCHEMBL3293027 | 0.84 | TAAR1 (1.00) | TAAR1IDO1AGXTSIGMAR1 | |
| (S)-M-Methoxyamphetamine SCHEMBL269071 | 0.84 | TAAR1 (1.00) | TAAR1IDO1AGXTSIGMAR1 | |
| (S)-M-Methoxyamphetamine SCHEMBL30813013 | 0.84 | TAAR1 (1.00) | TAAR1IDO1AGXTSIGMAR1 | |
| (S)-M-Methoxyamphetamine SCHEMBL11461072 | 0.84 | TAAR1 (1.00) | TAAR1IDO1AGXTSIGMAR1 | |
| SCHEMBL20683870 | 0.82 | TAAR1 (0.57) | TAAR1AOC3CHRM2CHRM1CHRM3 | |
| (S)-M-Methoxyamphetamine SCHEMBL30559562 | 0.82 | TAAR1 (0.96) | TAAR1IDO1AGXTSIGMAR1 | |
| SCHEMBL723511 | 0.81 | TAAR1 (0.77) | TAAR1AOC3CHRM2CHRM1CHRM3 | |
| SCHEMBL30080050 | 0.81 | TAAR1 (0.77) | TAAR1AOC3CHRM2CHRM1CHRM3 | |
| SCHEMBL7713131 | 0.81 | TAAR1 (0.57) | TAAR1AOC3CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431378-B2 | Aminotransferase, gene encoding the same, and methods of using them | KANEKA CORPORATION (JP) | 2013-04-30 | — | — | US | disclosed |
| US-20120164724-A1 | NOVEL AMINOTRANSFERASE, GENE ENCODING THE SAME, AND METHODS OF USING THEM | KANEKA CORPORATION (JP) | 2012-06-28 | — | — | US | disclosed |
| US-8133705-B2 | Aminotransferase, gene encoding the same, and method of using them | KANEKA CORPORATION (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20100285544-A1 | Novel aminotransferase, gene encoding the same, and method of using them | KANEKA CORPORATION (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-1889907-B1 | NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME | KANEKA CORP (JP) | 2009-09-02 | — | — | EP | disclosed |
| EP-1889907-A1 | NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME | Kaneka Corporation (JP) | 2008-02-20 | — | — | EP | disclosed |
| WO-2001064644-A1 | DICHLOROPYRIDYL- AND DICHLOROISOTHIAZOLYL-THIOCARBOXAMIDES AND THEIR USE AS MICROBICIDES | NIHON BAYER AGROCHEM K.K. (JP) | 2001-09-07 | — | — | WO | disclosed |
| EP-0114374-B1 | SUBSTITUTED 4-AMINOMETHYLENE CHROMANS OR CHROMENES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINES | BAYER AG (DE) | 1986-07-23 | — | — | EP | disclosed |
| US-4563458-A | CIRCULATORY SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-07 | — | — | US | disclosed |
| EP-0114374-A1 | Substituted 4-aminomethylene chromans or chromenes, process for their preparation and their use in medicines | BAYER AG (DE) | 1984-08-01 | — | — | EP | disclosed |
| EP-0007205-A1 | Optically active phenethanolamines, their formulations, use and preparation | ELI LILLY AND COMPANY (US) | 1980-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100285544-A1 | Novel aminotransferase, gene encoding the same, and method of using them | BCAT1, AGXT, ALDH7A1 | TAAR1 1322/4885AOC3 1000/4885CHRM2 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.